Volume 3 Supplement 2

30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015)

Open Access

Recent advances in adoptive cancer immunotherapy in china

  • Juhua Zhou1
Journal for ImmunoTherapy of Cancer20153(Suppl 2):P64

https://doi.org/10.1186/2051-1426-3-S2-P64

Published: 4 November 2015

Background

Cytokine-induced killer (CIK) cells have been extensively used in treatment of cancer patients in China. Clinical trials demonstrated that there were markedly decreased tumor nodules in size in a patient with advanced pancreatic adenocarcinoma following four cycles of CIK cell infusion and thus the patient had a longer progression-free survival. Moreover, immunotherapy with CIK cells in combination with chemotherapy had more potential benefits including longer progression-free survival and overall survival in patients with cancer such as advanced gastric cancer and non-small-cell lung cancer as compared with chemotherapy alone. In addition, dendritic cell (DC)-CIK cells have increased proliferation ability, cytokine secretion and anti-tumor activity as compared with CIK cells alone.

Results

A clinical trial showed that immunotherapy with tumor lysate-pulsed DC-CIK cells could significantly increase overall survival rates than no treatment control in renal cancer carcinoma patients. Thus, nowadays, DC-CIK cells have also been extensively used in treatment of cancer patients in China although the efficacy and mechanisms of adoptive cell transfer therapy with DC-CIK cells remains to be determined. In one word, the accumulation of basic researches and clinical studies related to cancer immunotherapy with CIK and DC-CIK cells has confirmed their safety and feasibility in treating malignant diseases. However, at present, there are still no uniform criteria or large-scale preparations of CIK and DC-CIK cells and the overall clinical response is difficult to evaluate due to lack of practical and appropriate criteria.

Conclusions

Large-scale, controlled, grouped, and multi-center clinical trials on CIK and DC-CIK cell-based immunotherapy should be conducted in the near future.

Declarations

Acknowledgements

Supported by “Taishan Scholar” special fund from Shandong Government, China.

Authors’ Affiliations

(1)
Ludong University

Copyright

© Zhou 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement